Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 6, 1998, Pages 622-635

  Hempel, Georg ^b   Karlsson, Mats O ^b   De Alwis, Dinesh P ^b   Toublanc, Nathalie ^b   McNay, John ^b   Schaefer, Hans G ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOXONIDINE;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; FEMALE; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; POPULATION RESEARCH; PRIORITY JOURNAL; SPHYGMOMANOMETRY;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0032422531     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90053-4     Document Type: Article

References (16)

1. Fogari R, Malacco E, Trettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24h ambulatory monitoring. Br J Clin Pharmacol 1993;35:51-4.
2. Cugini P, Leone G, DiPalma L, Battisti P, Wilson DW, Kawasaki T, et al. Construction of reference standards for blood pressure monitoring from womb to tomb. Statistician 1990;39:285-99.
3. Halberg J, Halberg F, Leach CN. Variability of human blood pressure with reference mostly to the non-chronobiologic literature. Chronobiologica 1984;11:205-16.
4. Machnig T, Engels G, Schoebel S, Gellert J, Bachmann K. A new approach for evaluating blood pressure levels and variability from 24h ambulatory blood pressure profiles. Am J Hypertens 1993;248-52.
5. Steimer JL, Ebelin ME, Van Bree J. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur J Drug Metab Pharmacokinet 1993;18:61-76.
6. Van Peer A, Snoeck E, Huang ML, Heykants J. Pharmacokinetic and pharmacodynamic relationships in phase I/phase II of drug development. Eur J Drug Metab Pharmacokinet 1993;18:49-59.
7. van Boxtel CJ, Holford NHG, Danhof M. The in vivo study of drug action. Amsterdam: Elsevier Science; 1992. p. 61.
8. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1997;5:445-79.
9. 1-imidazoline receptor agonist moxonidine: a new antihypertensive. 2nd ed. London: Royal Society of Medicine Press; 1996.
10. Karlsson MO, Sheiner LB. The importance of modelling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21:735-50.
11. Beal SL, Sheiner LB. NONMEM user's guide. San Francisco: NONMEM Project Group, University of California; 1992.
12. Morris STW, Reid JL. Moxonidine: a review. J Hum Hypertens 1997;11:629-35.
13. Witte K, Weisser K, Neubeck M, Mutschler E, Lehmann K, Hopf R, et al. Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration. Clin Pharmacol Ther 1993;54:177-86.
14. Streitberg B, Meyer-Sabellek W, Baumgart P. Statistical analysis of circadian blood pressure recordings in controlled clinical trials. J Hyperten 1989;7(suppl 3):S11-7.
15. Streitberg B, Meyer-Sabellek W. Smoothing twenty-four-hour ambulatory blood pressure profiles: a comparison of alternative methods. J Hyperten 1990;8(suppl 6):S21-7.
16. Marler M, Jacob RG, Lehoczky, Shapiro AP. The statistical analysis of treatment effects in 24-hour ambulatory blood pressure recordings. Stat Med 1988;7:697-716.